Hermes Vector

Health

FDA rejects Capricor's Duchenne cell therapy deramiocel over data integrity issues

The FDA declined to approve deramiocel for Duchenne muscular dystrophy, citing serious data integrity violations in the Phase 3 HOPE-3 trial that make the data unreliable.

By Hermes Vector

Also in: Español · Português · Français · Deutsch · हिन्दी

Checked against 3 sourcesmlq.aiwisevoter.comnews.ssbcrack.com
Illustration for: FDA rejects Capricor's Duchenne cell therapy deramiocel over data integrity issues

In brief

  • The FDA issued a complete response letter to Capricor on November 20 for deramiocel, its cell therapy for Duchenne muscular dystrophy.
  • FDA cited serious data integrity violations in the Phase 3 HOPE-3 study, including unauthorized post hoc changes to the statistical analysis plan and violations of blinding procedures.
  • Capricor says HOPE-2 and HOPE-3 both met their primary endpoints and that it stands behind the integrity of its data.
  • Capricor reported about $198.5 million in cash and securities at September 30, 2026.

FDA rejects Capricor's Duchenne cell therapy deramiocel over data integrity issues

The U.S. Food and Drug Administration has declined to approve deramiocel, Capricor Therapeutics's cell therapy for Duchenne muscular dystrophy, after finding serious data integrity violations in the company's Phase 3 HOPE-3 study.

FDA findings

The FDA issued a complete response letter to Capricor on November 20. The agency said its Bioresearch Monitoring Program inspected Capricor in connection with the application and found serious deficiencies in how HOPE-3 was run. The violations included "unauthorized post hoc changes to the statistical analysis plan; violations of study blinding procedures; and additional protocol violations."

The FDA said these problems "cannot be remediated post-hoc" and that the underlying data "cannot serve as a reliable foundation for a marketing approval determination." The agency also issued a Regulatory Responsibility Letter, dated November 20, covering its inspection observations, which Capricor can respond to.

Capricor's response

Capricor said HOPE-2 and HOPE-3 both met their primary endpoints and that it stands behind the integrity of its data. Chief executive Linda Marbán said: "Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval."

The company reported cash, cash equivalents, restricted cash and marketable securities of about $198.5 million at September 30, 2026, which it says is enough to fund planned operations for at least 12 months. It is reviewing the letter and will share next steps after its evaluation, and will hold a conference call and webcast on Monday, November 23, at 8:30 a.m. ET.

Why it matters

The rejection leaves patients with Duchenne muscular dystrophy without an FDA-approved cell therapy option for now. Any future access will depend on whether Capricor pursues a resubmission or additional studies.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

Why did the FDA reject Capricor's deramiocel therapy?
The FDA rejected the therapy due to serious data integrity violations found in the Phase 3 HOPE-3 study, including unauthorized post hoc changes to the statistical analysis plan and violations of study blinding procedures.
When did the FDA issue its decision on deramiocel?
The FDA issued a complete response letter to Capricor on November 20.
How does Capricor respond to the FDA's findings?
Capricor states that both HOPE-2 and HOPE-3 met their primary endpoints and that it stands behind the integrity of its data and the rigor of its clinical program.
What is the impact of this rejection on patients?
The rejection leaves patients with Duchenne muscular dystrophy without an FDA-approved cell therapy option for now.
When will Capricor hold a conference call to discuss next steps?
The company will hold a conference call and webcast on Monday, November 23, at 8:30 a.m. ET.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.

Health

American Cancer Society Updates Prostate Cancer Screening Guidelines

The American Cancer Society has updated its prostate cancer screening guidelines for the first time since 2010, recommending biennial PSA testing for average-risk men ages 50-69 and annual screening for higher-risk groups starting at age 45.

Checked against 6 sourceswfmz.comrenalandurologynews.comoncodaily.com+3 more